Title : Active Drug Targeting of a Folate-Based Cyclodextrin-Doxorubicin Conjugate and the Cytotoxic Effect on Drug-Resistant Mammary Tumor Cells In Vitro.

Pub. Date : 2015 Sep

PMID : 25940848






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In this study, we developed a cyclodextrin (CD)-based novel carrier-drug conjugate, called per-FOL-beta-CD-ss-DOX, which has folic acid (FA) molecules at the end of primary hydroxyl groups of beta-CD and a pH-cleavable spacer with an anticancer drug, doxorubicin (DOX), at the end of secondary hydroxyl groups. Cyclodextrins beta-carotene oxygenase 1 Mus musculus
2 In this study, we developed a cyclodextrin (CD)-based novel carrier-drug conjugate, called per-FOL-beta-CD-ss-DOX, which has folic acid (FA) molecules at the end of primary hydroxyl groups of beta-CD and a pH-cleavable spacer with an anticancer drug, doxorubicin (DOX), at the end of secondary hydroxyl groups. Cyclodextrins beta-carotene oxygenase 1 Mus musculus
3 In this study, we developed a cyclodextrin (CD)-based novel carrier-drug conjugate, called per-FOL-beta-CD-ss-DOX, which has folic acid (FA) molecules at the end of primary hydroxyl groups of beta-CD and a pH-cleavable spacer with an anticancer drug, doxorubicin (DOX), at the end of secondary hydroxyl groups. Cyclodextrins beta-carotene oxygenase 1 Mus musculus
4 In this study, we developed a cyclodextrin (CD)-based novel carrier-drug conjugate, called per-FOL-beta-CD-ss-DOX, which has folic acid (FA) molecules at the end of primary hydroxyl groups of beta-CD and a pH-cleavable spacer with an anticancer drug, doxorubicin (DOX), at the end of secondary hydroxyl groups. Cyclodextrins beta-carotene oxygenase 1 Mus musculus